long intergenic non-protein coding RNA 1343Genealiases: []
Q-omics provides the consensus-scored LINC01343 profile across patient tissues and cancer cell-line models. LINC01343 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01343 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, LINC01343 RNA expression shows 8,551 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, HNSC, and ESCA as cancer lineages where LINC01343 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01343 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01343 survival associations across molecular data types. LINC01343 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01343 RNA expression–survival associations across cancer types. High LINC01343 expression shows unfavorable associations in MESO, UCEC, LGG and CHOL, but favorable associations in ESCA and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01343 RNA expression.
This table summarizes LINC01343 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01343. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01343 shows lower tumor expression in PRAD and higher tumor expression in HNSC, KIRC, LUSC, KIRP and THCA. The HNSC box plot shows higher LINC01343 RNA expression in tumor versus normal tissue (log2 FC = +0.484, t-test p < 0.001).
This table shows molecular features associated with LINC01343 in patient tissues and cancer cell lines. In patient samples, LINC01343 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
